Acelyrin Belatedly Drops Izokibep In Its Lead Indications

 
• By Elizabeth Cairns
  
Generate a summary of this article
Listen to this article
Beta

The group has stopped further development of the IL-17A inhibitor in hidradenitis suppurativa and psoriatic arthritis, and intends to pivot to a thyroid eye disease therapy.  

Acelyrin HQ
• Source: Acelyrin

Acelyrin, Inc. has taken its time in coming to a sensible decision on izokibep. The company has terminated development of its IL-17A inhibitor izokibep in both hidradenitis suppurativa (HS) and psoriatic arthritis (PsA) after a Phase III trial in the former condition yielded positive but unremarkable data.

Key Takeaways

  • Acelyrin has canned izokibep in hidradenitis suppurativa and psoriatic arthritis after successful yet lackluster Phase III data in the former indication.

The company will now prioritize its only other pipeline drug, lonigutamab, which is in Phase II development for thyroid eye...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.